Related Experiment Video

Updated: Aug 22, 2026

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods
07:49

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

Published on: July 17, 2019

Inhibition of Ras oncogenic activity by Ras protooncogenes

Roberto Diaz1, Jeffrey Lue, Jeremy Mathews

  • 1Department of Pathology, New York University School of Medicine, 550 First Avenue, New York, NY 10016, USA.

International Journal of Cancer
|September 24, 2004
PubMed

Insights

Ras protooncogenes can inhibit oncogenic Ras activity, challenging the dogma of Ras oncogene dominance. This competition occurs at multiple cellular levels, with effects varying by cellular context.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Ras genes are frequently mutated in human tumors, leading to oncogenic Ras mutants.
  • These mutants are constitutively active, driving deregulated cell signaling and transformation.
  • The traditional view holds that Ras oncogenes are dominant, with a single mutated allele causing transformation.

Purpose of the Study:

  • To investigate the dominance of N-Ras oncogenes over Ras protooncogenes.
  • To explore the competitive interactions between Ras protooncogenes and N-Ras oncogenes.
  • To understand the mechanisms and cellular context dependency of Ras protooncogene inhibition on N-Ras oncogene activity.

Main Methods:

  • Co-expression studies in NIH 3T3 cells to assess Elk activation and focus formation.
  • Analysis of protein levels (p107, p130, cyclin A, Rb) in thymic lymphomas.
  • Investigating competitive inhibition at membrane and cytosolic effector levels.

Main Results:

  • Ras protooncogenes inhibit N-Ras oncogene activity in NIH 3T3 cells.
  • Inhibitory effect achieved through competition at effector and processing levels.
  • Coexpression of N-Ras protooncogene in lymphomas correlates with specific cell cycle regulator changes.
  • N-Ras oncogene dominance is not absolute and depends on cellular context.

Conclusions:

  • The N-Ras oncogene is not truly dominant over Ras protooncogenes.
  • Ras protooncogenes can counteract oncogenic Ras activity through competitive mechanisms.
  • The outcome of Ras protooncogene-oncogene interaction is influenced by the cellular environment.

More Related Videos

Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans08:12

Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans

Published on: October 5, 2020

Related Concept Videos

The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...
Small GTPases - Ras and Rho01:24

Small GTPases - Ras and Rho

Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...